Dr. Paul Palyca, MD

Dr. Palyca practices at Lehigh Valley Hospital-Cedar Crest in Allentown, Pennsylvania, part of Thomas Jefferson University.

Dr. Palyca's NPI, 1346545464, was assigned on January 20, 2011. Dr. Palyca graduated from Rutgers Robert Wood Johnson Medical School in 2009. Dr. Palyca holds Pennsylvania license MD455126.

Dr. Palyca's primary practice is Lehigh Valley Hospital-Cedar Crest, at 1200 South Cedar Crest Boulevard, Allentown, PA 18103 in Lehigh County. The practice phone is (610) 402-8000.

Dr. Palyca's primary practice is Lehigh Valley Hospital-Cedar Crest in Allentown, Pennsylvania, part of Thomas Jefferson University. Dr. Palyca is also affiliated with St. Luke's University Hospital - Bethlehem Campus. The medical group on file is Lehigh Valley Physician Group (LVPG). Dmand AI also links Dr. Palyca to 3 more hospitals, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Palyca practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Palyca's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Palyca is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Palyca's licenses on file in 2 states: Pennsylvania and New Jersey.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, fluid and electrolyte imbalances, immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Palyca treats.

CMS data shows 728 Medicare services from Dr. Palyca across 6 procedure codes in 2024, for 297 Medicare patients. Medicare paid $62,630 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 297 Medicare patients who saw Dr. Palyca in 2024. The largest group is 65 to 74, with 138 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.27, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Palyca's median patient age at 68, with 46% women.

In 2024, Dr. Palyca wrote 1,864 Medicare Part D claims for 188 patients. 71% of them were for generic drugs. CMS names the drug for 1,622 of them, across 30 drugs with 11 or more claims each, at $4,094,739 in total drug cost. In 2023, CMS named 1,366 claims across 30 drugs.

Dr. Palyca accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Palyca as offering telehealth.

Dmand AI links 3 papers to Dr. Palyca in 2023. 2023 was the busiest year, with 2. Dr. Palyca's most frequent co-authors are Ricardo Goncalves Alvim, MD, Andrea Borghese Apolo, MD and Angelo A. Baccala, MD.

CMS Open Payments shows 28 general payments to Dr. Palyca from 18 drug and device companies from 2017 to 2022. Food and beverage make up the largest share, 91% of the total. Sanofi and Genzyme US Companies paid the most, $264.

Dr. Palyca graduated from Rutgers Robert Wood Johnson Medical School in 2009.

Dr. Palyca is in network with 11 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.